Downward pressure on RCKT stock has been driven by broader sector-wide weakness in speculative biotechnology equities, cautious adjustments to near-term revenue expectations, clinical development milestone timelines, and general macroeconomic sentiment affecting high-growth pre-commercial healthcare firms.